Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127560181 | 12756018 | 1 | I | 20160913 | 20160916 | 20160916 | EXP | EG-JNJFOC-20160914702 | JANSSEN | HANY RA, MOHAMED S, ASMAA H, NAGLAA KE, MADEHA WE, DINA H. RESULTS OF TREATMENT OF LYMPHOBLASTIC LYMPHOMA AT THE CHILDREN CANCER HOSPITAL EGYPT ? A SINGLECENTER EXPERIENCE. JOURNAL OF THE EGYPTIAN NATIONAL CANCER INSTITUTE 01-SEP-2016;28 (3):175-181. | 0.00 | Y | 0.00000 | 20160916 | OT | EG | EG |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127560181 | 12756018 | 1 | SS | DOXORUBICIN HYDROCHLORIDE. | DOXORUBICIN HYDROCHLORIDE | 1 | Intravenous (not otherwise specified) | OVER 4 H INFUSION ON WEEK??1, 4, 7, 8, 11, 14 | U | U | 0 | 30 | MG/M**2 | LIPOSOME INJECTION | |||||
| 127560181 | 12756018 | 2 | PS | DOXORUBICIN HYDROCHLORIDE. | DOXORUBICIN HYDROCHLORIDE | 1 | Intravenous (not otherwise specified) | OVER 4 H INFUSION ON WEEK??1, 4, 7, 8, 11, 14 | U | U | 50718 | 30 | MG/M**2 | LIPOSOME INJECTION | |||||
| 127560181 | 12756018 | 3 | SS | VINCRISTINE | VINCRISTINE | 1 | Intravenous (not otherwise specified) | MAX DOSE 2 MG | U | 0 | 2 | MG/M**2 | UNSPECIFIED | ||||||
| 127560181 | 12756018 | 4 | SS | VINCRISTINE | VINCRISTINE | 1 | Intravenous (not otherwise specified) | MAX 2 MG ON DAYS 1,8,15 AND 22 | U | 0 | 1.5 | MG/M**2 | UNSPECIFIED | ||||||
| 127560181 | 12756018 | 5 | SS | VINCRISTINE | VINCRISTINE | 1 | Intravenous (not otherwise specified) | MAX DOSE 2 MG | U | 0 | 2 | MG/M**2 | UNSPECIFIED | ||||||
| 127560181 | 12756018 | 6 | SS | VINCRISTINE | VINCRISTINE | 1 | Intravenous (not otherwise specified) | MAX 2 MG ON DAYS 1,8,15 AND 22 | U | 0 | 1.5 | MG/M**2 | UNSPECIFIED | ||||||
| 127560181 | 12756018 | 7 | SS | DEXAMETHASONE. | DEXAMETHASONE | 1 | Oral | 12 MG IN THREE DOSES DAILY FOR 5 DAYS EVERY 28 DAYS | U | 0 | 12 | MG/M**2 | UNSPECIFIED | ||||||
| 127560181 | 12756018 | 8 | SS | DEXAMETHASONE. | DEXAMETHASONE | 1 | Oral | 12 MG IN THREE DOSES DAILY FOR 5 DAYS EVERY 28 DAYS | U | 0 | 12 | MG/M**2 | UNSPECIFIED | ||||||
| 127560181 | 12756018 | 9 | SS | METHOTREXATE. | METHOTREXATE | 1 | Intramuscular | FOR 28 DAYS | U | 0 | 40 | MG/M**2 | UNSPECIFIED | ||||||
| 127560181 | 12756018 | 10 | SS | METHOTREXATE. | METHOTREXATE | 1 | Intramuscular | FOR 28 DAYS | U | 0 | 40 | MG/M**2 | UNSPECIFIED | ||||||
| 127560181 | 12756018 | 11 | SS | ASPARAGINASE | ASPARAGINASE | 1 | Intramuscular | 25,000 IU/M2/DAY ON 1,5,9,11,13 AND ON WEEK 1-19 | U | 0 | UNSPECIFIED | ||||||||
| 127560181 | 12756018 | 12 | SS | ASPARAGINASE | ASPARAGINASE | 1 | Intramuscular | 25,000 IU/M2/DAY ON 1,5,9,11,13 AND ON WEEK 1-19 | U | 0 | UNSPECIFIED | ||||||||
| 127560181 | 12756018 | 13 | SS | CYCLOPHOSPHAMIDE. | CYCLOPHOSPHAMIDE | 1 | Intrathecal | FOR 12 DOSES | U | 0 | 300 | MG/M**2 | UNSPECIFIED | ||||||
| 127560181 | 12756018 | 14 | SS | CYCLOPHOSPHAMIDE. | CYCLOPHOSPHAMIDE | 1 | Intrathecal | ON DAY 2 | U | 0 | 1000 | MG/M**2 | UNSPECIFIED | ||||||
| 127560181 | 12756018 | 15 | SS | CYCLOPHOSPHAMIDE. | CYCLOPHOSPHAMIDE | 1 | Intrathecal | FOR 12 DOSES | U | 0 | 300 | MG/M**2 | UNSPECIFIED | ||||||
| 127560181 | 12756018 | 16 | SS | CYCLOPHOSPHAMIDE. | CYCLOPHOSPHAMIDE | 1 | Intrathecal | ON DAY 2 | U | 0 | 1000 | MG/M**2 | UNSPECIFIED | ||||||
| 127560181 | 12756018 | 17 | SS | ARA-C | CYTARABINE | 1 | Intravenous (not otherwise specified) | FOR 12 DOSES | U | 0 | 300 | MG/M**2 | UNSPECIFIED | ||||||
| 127560181 | 12756018 | 18 | SS | ARA-C | CYTARABINE | 1 | Intravenous (not otherwise specified) | FOR 12 DOSES | U | 0 | 300 | MG/M**2 | UNSPECIFIED | ||||||
| 127560181 | 12756018 | 19 | SS | PREDNISONE. | PREDNISONE | 1 | Unknown | FOR 28 DAYS | U | 0 | 40 | MG/M**2 | UNSPECIFIED | ||||||
| 127560181 | 12756018 | 20 | SS | PREDNISONE. | PREDNISONE | 1 | Unknown | FOR 28 DAYS | U | 0 | 40 | MG/M**2 | UNSPECIFIED | ||||||
| 127560181 | 12756018 | 21 | SS | MERCAPTOPURINE. | MERCAPTOPURINE | 1 | Intrathecal | EVERY TWO WEEKS FOR 4 DOSES | U | 0 | 50 | MG/M**2 | UNSPECIFIED | ||||||
| 127560181 | 12756018 | 22 | SS | MERCAPTOPURINE. | MERCAPTOPURINE | 1 | Intrathecal | U | 0 | 40 | MG/M**2 | UNSPECIFIED | |||||||
| 127560181 | 12756018 | 23 | SS | MERCAPTOPURINE. | MERCAPTOPURINE | 1 | Intrathecal | DAYS 23?36 | U | 0 | 60 | MG/M**2 | UNSPECIFIED | ||||||
| 127560181 | 12756018 | 24 | SS | MERCAPTOPURINE. | MERCAPTOPURINE | 1 | Intrathecal | EVERY TWO WEEKS FOR 4 DOSES | U | 0 | 50 | MG/M**2 | UNSPECIFIED | ||||||
| 127560181 | 12756018 | 25 | SS | MERCAPTOPURINE. | MERCAPTOPURINE | 1 | Intrathecal | DAYS 23?36 | U | 0 | 60 | MG/M**2 | UNSPECIFIED | ||||||
| 127560181 | 12756018 | 26 | SS | MERCAPTOPURINE. | MERCAPTOPURINE | 1 | Intrathecal | U | 0 | 40 | MG/M**2 | UNSPECIFIED | |||||||
| 127560181 | 12756018 | 27 | SS | DAUNORUBICIN | DAUNORUBICIN | 1 | Unknown | DAYS 1 AND 8 | U | 0 | 30 | MG/M**2 | UNSPECIFIED | ||||||
| 127560181 | 12756018 | 28 | SS | DAUNORUBICIN | DAUNORUBICIN | 1 | Unknown | DAYS 1 AND 8 | U | 0 | 30 | MG/M**2 | UNSPECIFIED | ||||||
| 127560181 | 12756018 | 29 | SS | CYTARABINE. | CYTARABINE | 1 | Intrathecal | DAYS 23?26, AND 32?35 | U | 0 | 75 | MG/M**2 | UNSPECIFIED | ||||||
| 127560181 | 12756018 | 30 | SS | CYTARABINE. | CYTARABINE | 1 | Intrathecal | DAYS 23?26, AND 32?35 | U | 0 | 75 | MG/M**2 | UNSPECIFIED |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127560181 | 12756018 | 1 | Acute lymphocytic leukaemia |
| 127560181 | 12756018 | 2 | Non-Hodgkin's lymphoma |
| 127560181 | 12756018 | 3 | Acute lymphocytic leukaemia |
| 127560181 | 12756018 | 4 | Acute lymphocytic leukaemia |
| 127560181 | 12756018 | 5 | Non-Hodgkin's lymphoma |
| 127560181 | 12756018 | 6 | Non-Hodgkin's lymphoma |
| 127560181 | 12756018 | 7 | Acute lymphocytic leukaemia |
| 127560181 | 12756018 | 8 | Non-Hodgkin's lymphoma |
| 127560181 | 12756018 | 9 | Acute lymphocytic leukaemia |
| 127560181 | 12756018 | 10 | Non-Hodgkin's lymphoma |
| 127560181 | 12756018 | 11 | Acute lymphocytic leukaemia |
| 127560181 | 12756018 | 12 | Non-Hodgkin's lymphoma |
| 127560181 | 12756018 | 13 | Acute lymphocytic leukaemia |
| 127560181 | 12756018 | 14 | Acute lymphocytic leukaemia |
| 127560181 | 12756018 | 15 | Non-Hodgkin's lymphoma |
| 127560181 | 12756018 | 16 | Non-Hodgkin's lymphoma |
| 127560181 | 12756018 | 17 | Acute lymphocytic leukaemia |
| 127560181 | 12756018 | 18 | Non-Hodgkin's lymphoma |
| 127560181 | 12756018 | 19 | Acute lymphocytic leukaemia |
| 127560181 | 12756018 | 20 | Non-Hodgkin's lymphoma |
| 127560181 | 12756018 | 21 | Acute lymphocytic leukaemia |
| 127560181 | 12756018 | 22 | Acute lymphocytic leukaemia |
| 127560181 | 12756018 | 23 | Acute lymphocytic leukaemia |
| 127560181 | 12756018 | 24 | Non-Hodgkin's lymphoma |
| 127560181 | 12756018 | 25 | Non-Hodgkin's lymphoma |
| 127560181 | 12756018 | 26 | Non-Hodgkin's lymphoma |
| 127560181 | 12756018 | 27 | Acute lymphocytic leukaemia |
| 127560181 | 12756018 | 28 | Non-Hodgkin's lymphoma |
| 127560181 | 12756018 | 29 | Acute lymphocytic leukaemia |
| 127560181 | 12756018 | 30 | Non-Hodgkin's lymphoma |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127560181 | 12756018 | OT |
| 127560181 | 12756018 | DE |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127560181 | 12756018 | Bone infarction | |
| 127560181 | 12756018 | Cardiotoxicity | |
| 127560181 | 12756018 | Cerebral infarction | |
| 127560181 | 12756018 | Off label use | |
| 127560181 | 12756018 | Osteonecrosis | |
| 127560181 | 12756018 | Osteopenia | |
| 127560181 | 12756018 | Pancreatic disorder | |
| 127560181 | 12756018 | Pathological fracture | |
| 127560181 | 12756018 | Posterior reversible encephalopathy syndrome | |
| 127560181 | 12756018 | Product use issue | |
| 127560181 | 12756018 | Pulmonary toxicity | |
| 127560181 | 12756018 | Thrombosis |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |